BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30998199)

  • 1. [Multiple myeloma immunophenotyping: method validation].
    Vergnolle I; Rieu JB; Avet-Loiseau H; Corre J; Vergez F
    Ann Biol Clin (Paris); 2019 Apr; 77(2):197-217. PubMed ID: 30998199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
    Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
    Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.
    Frébet E; Abraham J; Geneviève F; Lepelley P; Daliphard S; Bardet V; Amsellem S; Guy J; Mullier F; Durrieu F; Venon MD; Leleu X; Jaccard A; Faucher JL; Béné MC; Feuillard J;
    Cytometry B Clin Cytom; 2011 May; 80(3):176-85. PubMed ID: 21520405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.
    Manasanch EE; Salem DA; Yuan CM; Tageja N; Bhutani M; Kwok M; Kazandjian D; Carter G; Steinberg SM; Zuchlinski D; Mulquin M; Calvo K; Maric I; Roschewski M; Korde N; Braylan R; Landgren O; Stetler-Stevenson M
    Leuk Lymphoma; 2015 May; 56(5):1416-24. PubMed ID: 25263319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.
    Raja KR; Kovarova L; Hajek R
    Br J Haematol; 2010 May; 149(3):334-51. PubMed ID: 20201947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
    Tembhare PR; Yuan CM; Venzon D; Braylan R; Korde N; Manasanch E; Zuchlinsky D; Calvo K; Kurlander R; Bhutani M; Tageja N; Maric I; Mulquin M; Roschewski M; Kwok M; Liewehr D; Landgren O; Stetler-Stevenson M
    Leuk Res; 2014 Mar; 38(3):371-6. PubMed ID: 24462038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
    Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
    Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
    Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.
    Yuan CM; Stetler-Stevenson M
    Semin Hematol; 2011 Jan; 48(1):32-8. PubMed ID: 21232656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable disease evaluation in patients with myeloma.
    Roshal M
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101154. PubMed ID: 32139019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLOCK cluster analysis of plasma cell flow cytometry data predicts bone marrow involvement by plasma cell neoplasia.
    Dorfman DM; LaPlante CD; Li B
    Leuk Res; 2016 Sep; 48():40-5. PubMed ID: 27479652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
    Requirand G; Robert N; Boireau S; Vincent L; Seckinger A; Bouhya S; Ceballos P; Cartron G; Hose D; Klein B; Moreaux J
    Cytometry B Clin Cytom; 2019 May; 96(3):209-214. PubMed ID: 30417559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
    Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparameter immunophenotyping by flow cytometry as a diagnostic tool in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Carulli G; Ottaviano V; Cannizzo E; Giuntini S; Manetti C; Ciancia EM; Azzarà A
    Clin Ter; 2012; 163(5):387-92. PubMed ID: 23099966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.
    Hughes D; Yong K; Ramasamy K; Stern S; Boyle E; Ashcroft J; Basheer F; Rabin N; Pratt G
    Br J Haematol; 2024 Apr; 204(4):1193-1206. PubMed ID: 38393718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the diagnosis and management of myeloma.
    Greipp PR
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):24-45. PubMed ID: 1509293
    [No Abstract]   [Full Text] [Related]  

  • 19. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
    Rawstron AC; Orfao A; Beksac M; Bezdickova L; Brooimans RA; Bumbea H; Dalva K; Fuhler G; Gratama J; Hose D; Kovarova L; Lioznov M; Mateo G; Morilla R; Mylin AK; Omedé P; Pellat-Deceunynck C; Perez Andres M; Petrucci M; Ruggeri M; Rymkiewicz G; Schmitz A; Schreder M; Seynaeve C; Spacek M; de Tute RM; Van Valckenborgh E; Weston-Bell N; Owen RG; San Miguel JF; Sonneveld P; Johnsen HE;
    Haematologica; 2008 Mar; 93(3):431-8. PubMed ID: 18268286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
    Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
    Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.